Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1
Clinical development program continues to evaluate safety and immunogenicity.
The registration of a new vaccine which took around 50 years to develop, is set to offer older Kiwis protection against RSV-associated lower respiratory tract disease for the first time.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus substantially reduced RSV lower respiratory tract.